by David Kent | Jul 18, 2016
During the morning plenary session on the final day of ISSCR, we were treated to a delightful mix of basic and translational science as well as a riveting public policy lecture from Alta Charo. The session was all about disease modeling and stem cells and the...
by Mark Curtis | May 25, 2015
. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn...
by Sara M. Nolte | May 19, 2015
. I’ve spent a number of posts going on and on about how targeting cancer stem cells (CSCs) is the next big thing for cancer therapies, and how important it is that we study and learn all we can about them (know your enemy, right?). All of this has probably left you...
by Lisa Willemse | Apr 25, 2014
> Julia Pon is a MD/PhD student at the University of British Columbia with an interest in blood cancer. Like many before her, she noticed that the kind of information that is shared with cancer patients is different than what medical students are taught about the...
by Mark Curtis | Oct 17, 2013
. Welcome to the first Regenerative Medicine Deal Review, an overview of recent licensing, partnering, and financing activity all exclusively in the regenerative medicine and cell therapy industries. Like my first post ‘Update from the Clinic’, this piece is intended...
Comments